Literature DB >> 6206831

Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism.

Y Stern, R Mayeux, L Côté.   

Abstract

Delayed reaction time and diminished vigilance have been observed in Parkinson's disease (PD) but have not been related to biochemical changes in the disease. As norepinephrine is reduced in the brain in PD and this neurotransmitter has been related to attention and learning, we investigated the relationship of neuropsychological measures, including those of reaction time and vigilance, to the norepinephrine metabolite 3-methoxy - 4 - hydroxyphenethyleneglycol (MHPG) in 39 patients with idiopathic PD. The MHPG levels correlated with a measure of general intellectual ability and with performance on reaction time and continuous performance tasks. Our data suggest that altered norepinephrine metabolism may contribute to some aspects of intellectual dysfunction in PD.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206831     DOI: 10.1001/archneur.1984.04050210084021

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  13 in total

1.  Cognitive components of reaction time in Parkinson's disease.

Authors:  N Jordan; H J Sagar; J A Cooper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-08       Impact factor: 10.154

2.  Behavioral toxicology of cognition: extrapolation from experimental animal models to humans: behavioral toxicology symposium overview.

Authors:  Merle G Paule; Leonard Green; Joel Myerson; Maria Alvarado; Jocelyne Bachevalier; Jay S Schneider; Susan L Schantz
Journal:  Neurotoxicol Teratol       Date:  2012-01-28       Impact factor: 3.763

3.  Is there a specific visuo-spatial impairment in Parkinsonians?

Authors:  S Della Sala; G Di Lorenzo; A Giordano; H Spinnler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

4.  Covert orienting attention in Parkinson's disease.

Authors:  T Yamada; M Izyuuinn; M Schulzer; K Hirayama
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

5.  Abnormal refractoriness in patients with Parkinson's disease after brief withdrawal of levodopa treatment.

Authors:  J Harrison; L Henderson; C Kennard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-11       Impact factor: 10.154

Review 6.  Early Parkinson's disease: what is the best approach to treatment.

Authors:  A H Hristova; W C Koller
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

7.  Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease.

Authors:  Kamin Kim; Nicolaas I Bohnen; Martijn L T M Müller; Cindy Lustig
Journal:  Neuroimage       Date:  2018-01-11       Impact factor: 6.556

8.  Usefulness of movement time in the assessment of Parkinson's disease.

Authors:  M Zappia; R Montesanti; R Colao; A Quattrone
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

9.  Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

Authors:  Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R Williams
Journal:  Mov Disord       Date:  2009-01-30       Impact factor: 10.338

10.  Noradrenaline and Parkinson's disease.

Authors:  Claire Delaville; Philippe De Deurwaerdère; Abdelhamid Benazzouz
Journal:  Front Syst Neurosci       Date:  2011-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.